2022-08-04 | NDAQ:BNR | Press release

GUANGZHOU, China, Aug. 04, 2022 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next-generation sequencing (NGS) technology ) in precision oncology, today announced that it intends to release its unaudited financial results for the second quarter of 2022 prior to the U.S. market open on August 31, 2022. Following this release, management of the company will host a conference call at 8:30 a.m. ET (8:30 p.m. HK time) on the same day to discuss its financial results for the second quarter of 2022.

Although the company has not completed preparing its financial statements for the second quarter of 2022, it expects to report moderate year-over-year revenue growth, driven by new product launches and growth. continued growth in its pharmaceutical services revenues, offsetting the decline in the impact of the COVID-19-related lockdowns which strongly impacted its business volumes in the regions concerned.

Please register prior to the conference using the link provided below and dial 15 minutes prior to the call, using the attendee dial-in numbers and incumbent unique identifier that will be provided during registration.

PRE-REGISTRATION LINK: https://register.vevent.com/register/BI1f6043e15b804286b8c6f5db40d78456.

In addition, a live and archived webcast of the conference call will also be available on the Company’s Investor Relations website at http://ir.brbiotech.com or by link https://edge.media-server.com/mmc/p/57gam4s5.

A replay of the webcast will be available for 12 months via the same link above.

Please visit the Company’s Investor Relations website at https://ir.brbiotech.com/news-events/news-releases on August 31, 2022 to consult the publication of the results before the conference call.

About Burning Rock

Burning Rock Biotech Limited (NASDAQ:BNR), whose mission is to protect life through science, focuses on the application of next-generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection tests for advanced-stage cancer patients, and ii) NGS-based early cancer detection, which has grown from evidence R&D from concept to clinical validation.

For more information on Burning Rock, please visit: www.brbiotech.com.

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “target,” “confident” and similar statements. Burning Rock may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials, and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Burning Rock’s beliefs and expectations, are forward-looking statements. Such statements are based current expectations of management and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond Burning Rock’ control. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in such statements. All information provided in this press release is as of the date of this press release, and Burning Rock undertakes no obligation to update any forward-looking statement as a result of new information, future events or otherwise, unless applicable law requires it. .

Contact: IR@brbiotech.com

main logo

Comments are closed.